Skip to main content

Table 4 Toxic effects occurring during treatment of advanced breast cancer with PLD (described in at least 2 PLD-treated patients).

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Toxic effects N (%)
PPE 22 (17)
   Grade 1 11 (9)
   Grade 2 9 (7)
   Grade 3 1 (1)
Exanthema 18 (14)
Mucositis 16 (12)
Nausea/Vomiting 12 (9)
Fatigue 11 (9)
Infectious event 12 (9)
Alopecia (only grade 1 and 2) 7 (5)
Gastrointestinal problems 6 (5)
Respiratory problems 5 (4)
Cardiac problems* 5 (4)
Neutropenia grade 4 3 (2)
Thrombocytopenia grade 4 2 (2)
Thromboembolic event 2 (2)
Cough 2 (2)
Hypersensitivity reaction 2 (2)
  1. *Including 2 patients with severe congestive heart failure, one case of which was fatal. 4 patients with cardiac adverse events during PLD therapy harboured 2 cardiac risk factors, whereas the one patient with fatal exacerbation of heart failure was characterized by 5 cardiac risk factors.